{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T19:02:39Z","timestamp":1778958159431,"version":"3.51.4"},"reference-count":50,"publisher":"BMJ","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"accepted":{"date-parts":[[2023,8,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To report the efficacy, safety, and exploratory immunogenicity findings of two 5 \u00b5g doses of the BIV1-CovIran vaccine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>In six cities of Iran, including Bushehr, Isfahan, Karaj, Mashhad, Shiraz, and Tehran. The first vaccine or placebo injection of the first participant was on 16 May 2021 in Tehran. The last vaccine or placebo injection of the last participant occurred on 15 July 2021 in Isfahan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>20\u2009000 participants aged 18-75 years were randomly assigned to the intervention or placebo groups with a ratio of 2:1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>5 \u00b5g vaccine or placebo with the interval of 28 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>Vaccine efficacy for a 90 day follow-up period, safety and explanatory immunogenicity assessment, and variant detection during the trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>20\u2009000 participants were recruited and randomly assigned to receive BIV1-CovIran (n=13\u2009335 (66.7%)) or placebo (n=6665 (33.3%)). Participants' mean age was 38.3 (standard deviation 11.2) years, and 6913 (34.6%) were female. Among vaccinated participants that had covid-19 reported during the follow-up (median 83 days), 758 (5.9%) had symptoms, 144 (1.1%) had severe infection, and seven (0.1%) were critical. Among participants who received placebo during the follow-up, 688 (10.7%) had symptoms, 221 (3.4%) had severe infection, and 19 (0.3%) were critical. Overall efficacy was 50.2% (95% confidence interval 44.7% to 55.0%) against symptomatic covid-19, 70.5% (63.7% to 76.1%) against severe disease, and 83.1% (61.2% to 93.5%) against critical cases. Two deaths were reported in the efficacy population in the placebo group, no deaths were from the intervention group. During follow-up, 41\u2009922 adverse events were reported: 28\u2009782 (68.7%) were adverse reactions, of which 19\u2009363 (67.3%) were in the intervention group. Most adverse reactions were mild or moderate in severity (grade 1 or 2) and self-limiting. No serious adverse events were related to the injections. For variant investigation, of 119 participants positive for the SARS-CoV-2 variant, 106 (89.1%) were positive for the delta variant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A two dose regimen of the BIV1-CovIran vaccine conferred efficacy of 50.2% against symptomatic covid-19, 70.5% against severe disease, and 83.1% against critical disease. Vaccination was well tolerated, with no safety concerns raised.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Iranian Registry of Clinical Trials, IRCT20201202049567N3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Funding<\/jats:title>\n                    <jats:p>Shifa-Pharmed Industrial Group.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmj-2023-070464","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T08:30:16Z","timestamp":1695285016000},"page":"e070464","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial"],"prefix":"10.1136","volume":"382","author":[{"given":"Minoo","family":"Mohraz","sequence":"first","affiliation":[{"name":"Iranian Research Center for HIV\/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katayoun","family":"Vahdat","sequence":"additional","affiliation":[{"name":"The Persian Gulf Tropical Medicine Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyyed-Hadi","family":"Ghamari","sequence":"additional","affiliation":[{"name":"Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Abbasi-Kangevari","sequence":"additional","affiliation":[{"name":"Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erfan","family":"Ghasemi","sequence":"additional","affiliation":[{"name":"Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasaman","family":"Ghabdian","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Negar","family":"Rezaei","sequence":"additional","affiliation":[{"name":"Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran"},{"name":"Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam Amini","family":"Pouya","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Faculty of pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asghar","family":"Abdoli","sequence":"additional","affiliation":[{"name":"Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran"},{"name":"Amirabad Virology Laboratory, Vaccine Unit, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad-Reza","family":"Malekpour","sequence":"additional","affiliation":[{"name":"Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keyvan","family":"Koohgir","sequence":"additional","affiliation":[{"name":"School of Medicine, Shahroud University of Medical Sciences, Semnan, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar","family":"Saeedi Moghaddam","sequence":"additional","affiliation":[{"name":"Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Payam","family":"Tabarsi","sequence":"additional","affiliation":[{"name":"Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Moghadami","sequence":"additional","affiliation":[{"name":"Non\u2010Communicable Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzin","family":"Khorvash","sequence":"additional","affiliation":[{"name":"Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rozita","family":"Khodashahi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Tropical Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5538-7586","authenticated-orcid":false,"given":"Mohammadreza","family":"Salehi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Tropical Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamed","family":"Hosseini","sequence":"additional","affiliation":[{"name":"Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran."},{"name":"Clinical Trial Center, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"key":"2025110102190131000_382.sep21_11.e070464.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30120-1"},{"key":"2025110102190131000_382.sep21_11.e070464.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2107528"},{"key":"2025110102190131000_382.sep21_11.e070464.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01230-y"},{"key":"2025110102190131000_382.sep21_11.e070464.4","unstructured":"World Health Organization. Draft landscape and tracker of COVID-19 candidate vaccines. Date accessed 17 May 2021."},{"key":"2025110102190131000_382.sep21_11.e070464.5","unstructured":"World Health Organization. COVID-19 vaccines. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/covid-19-vaccines (accessed 16 Oct 2021)."},{"key":"2025110102190131000_382.sep21_11.e070464.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00475-8"},{"key":"2025110102190131000_382.sep21_11.e070464.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2108891"},{"key":"2025110102190131000_382.sep21_11.e070464.8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-056872"},{"key":"2025110102190131000_382.sep21_11.e070464.9","doi-asserted-by":"publisher","DOI":"10.1002\/RMV.2305"},{"key":"2025110102190131000_382.sep21_11.e070464.10","unstructured":"World Health Organization. Weekly epidemiological update on COVID-19 - 8 June 2021. https:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update-on-covid-19-8-june-2021 (accessed 17 Oct 2021)."},{"key":"2025110102190131000_382.sep21_11.e070464.11","unstructured":"Statistical Center of Iran. Iran Statistical Yearbook. Iran Statistical Yearbook 2019-2020. https:\/\/www.amar.org.ir\/english\/Iran-Statistical-Yearbook\/Iran-Statistical-Yearbook-2019-2020 (accessed 4 Jun 2022)."},{"key":"2025110102190131000_382.sep21_11.e070464.12","unstructured":"Sealed Envelope. Randomisation (randomization) and online databases for clinical trials. https:\/\/www.sealedenvelope.com\/ (accessed 4 Jun 2022)."},{"key":"2025110102190131000_382.sep21_11.e070464.13","doi-asserted-by":"publisher","DOI":"10.1002\/RMV.2305"},{"key":"2025110102190131000_382.sep21_11.e070464.14","unstructured":"World Health Organization. Therapeutics and COVID-19: living guideline. 24 September 2021. Geneva: World Health Organization."},{"key":"2025110102190131000_382.sep21_11.e070464.15","unstructured":"Food and Drug Administration. Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical (accessed 11 Dec 2021)."},{"key":"2025110102190131000_382.sep21_11.e070464.16","unstructured":"World Health Organization. An international randomised trial of candidate vaccines against COVID-19. https:\/\/www.who.int\/publications\/i\/item\/an-international-randomised-trial-of-candidate-vaccines-against-covid-19 (accessed 30 Oct 2021)."},{"key":"2025110102190131000_382.sep21_11.e070464.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00070-0"},{"key":"2025110102190131000_382.sep21_11.e070464.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30843-4"},{"key":"2025110102190131000_382.sep21_11.e070464.19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.15543"},{"key":"2025110102190131000_382.sep21_11.e070464.20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.8565"},{"key":"2025110102190131000_382.sep21_11.e070464.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02000-6"},{"key":"2025110102190131000_382.sep21_11.e070464.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2639-4"},{"key":"2025110102190131000_382.sep21_11.e070464.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022483"},{"key":"2025110102190131000_382.sep21_11.e070464.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31604-4"},{"key":"2025110102190131000_382.sep21_11.e070464.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027906"},{"key":"2025110102190131000_382.sep21_11.e070464.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32661-1"},{"key":"2025110102190131000_382.sep21_11.e070464.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102214"},{"key":"2025110102190131000_382.sep21_11.e070464.28","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30120-1"},{"key":"2025110102190131000_382.sep21_11.e070464.29","unstructured":"Threat Assessment Brief. Emergence of SARS-CoV-2 B.1.617 variants in India and situation in the EU\/EEA. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/threat-assessment-emergence-sars-cov-2-b1617-variants (accessed 3 Nov 2021)."},{"key":"2025110102190131000_382.sep21_11.e070464.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03237-4"},{"key":"2025110102190131000_382.sep21_11.e070464.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.07.012"},{"key":"2025110102190131000_382.sep21_11.e070464.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2108891"},{"key":"2025110102190131000_382.sep21_11.e070464.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2119912"},{"key":"2025110102190131000_382.sep21_11.e070464.34","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn8652"},{"key":"2025110102190131000_382.sep21_11.e070464.35","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00559-2"},{"key":"2025110102190131000_382.sep21_11.e070464.36","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27697"},{"key":"2025110102190131000_382.sep21_11.e070464.37","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-03592-2"},{"key":"2025110102190131000_382.sep21_11.e070464.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.12.032"},{"key":"2025110102190131000_382.sep21_11.e070464.39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-069989"},{"key":"2025110102190131000_382.sep21_11.e070464.40","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27530"},{"key":"2025110102190131000_382.sep21_11.e070464.41","unstructured":"Mohraz M, Abbasi-Kangevari M, Ghamari S-H, et al. Immunogenicity and safety of a variant-specific covid-19 vaccine booster, BIV1-coviran plus: findings from a non-inferiority, parallel-design non-randomised clinical trial. SSRN https:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=4189405 (accessed 2 Dec 2022)."},{"key":"2025110102190131000_382.sep21_11.e070464.42","unstructured":"Abdoli A, Khanali J, Azangou-Khyavy M, et al. Omicron-based vaccine candidate elicits potent neutralizing antibodies in the animal model. BioRxiv https:\/\/www.biorxiv.org\/content\/10.1101\/2022.02.11.480131v1 (accessed 2 Dec 2022)."},{"key":"2025110102190131000_382.sep21_11.e070464.43","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.8565"},{"key":"2025110102190131000_382.sep21_11.e070464.44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114255"},{"key":"2025110102190131000_382.sep21_11.e070464.45","unstructured":"World Bank. Individuals using the Internet (% of population) - Iran, Islamic Rep. Data. https:\/\/data.worldbank.org\/indicator\/IT.NET.USER.ZS?locations=IR (accessed 5 May 2023)."},{"key":"2025110102190131000_382.sep21_11.e070464.46","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00146-3"},{"key":"2025110102190131000_382.sep21_11.e070464.47","unstructured":"World Health Organization. Evidence assessment: Sinopharm\/BBIBP COVID-19 vaccine. 2021-04-29. https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/sage\/2021\/april\/2_sage29apr2021_critical-evidence_sinopharm.pdf. 2021."},{"key":"2025110102190131000_382.sep21_11.e070464.48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105290"},{"key":"2025110102190131000_382.sep21_11.e070464.49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110345"},{"key":"2025110102190131000_382.sep21_11.e070464.50","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01429-X"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj-2023-070464","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj-2023-070464","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:19:08Z","timestamp":1761988748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj-2023-070464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":50,"alternative-id":["10.1136\/bmj-2023-070464"],"URL":"https:\/\/doi.org\/10.1136\/bmj-2023-070464","relation":{},"ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,21]]}}}